Memo Therapeutics AG

PureTech Health plc, after the multibillion-dollar success of its last neuropsychiatry venture Karuna Therapeutics Inc., launched Seaport Therapeutics in April with $100m in series A funding and on 21

With rising interest in inflammation and immunology – likely in response to large deals in the I&I space as much as unmet needs in autoimmune diseases – venture capital investors have put big money in

October ended and November began with the announcement of three new venture capital and equity funds with more than $1.3bn for health care, life science and biopharmaceutical investments. Revelation P

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Eisai Divests Asian Rights For Two